Details

Autor(en) / Beteiligte

• Vijverberg, Susanne J H
• Tavendale, Roger
• Leusink, Maarten
• Koenderman, Leo
• Raaijmakers, Jan A M
• Postma, Dirkje S
• Koppelman, Gerard H
• Turner, Steve W
• Mukhopadhyay, Somnath
• Palmer, Colin N A
• Maitland-van der Zee, Anke Hilse

Titel

Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

Ist Teil von

• Pharmacogenomics, 2014-04, Vol.15 (6), p.799-806

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics. To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS. rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire. rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary β: 0.01, 95% CI: -0.06-0.08). Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children. Original submitted 26 November 2013; Revision submitted 13 February 2014.